Day 2 - Friday, March 1, 2024

Daily News Day 2 | 2024 Multidisciplinary Head and Neck Cancers Symposium

Read the Daily News for highlights from Day 2.

A Step Toward More Personalized Therapy for Patients with Recurrent/Metastatic HNSCC with a Novel Immunotherapy Selection Strategy Based upon Immune Gene Expression

Dan Zandberg, MD, and colleagues from UPMC Hillman Cancer Center presented the results of their prospective phase II study of personalized immunotherapy that seeks to enhance treatment outcomes for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), whose disease has progressed on anti-PD-1 or anti-PD-L1 monoclonal antibody (mAb) therapy.

HPV serology and HPV ctDNA sequencing in p16+ Oropharyngeal Cancer Patients

As the incidence of human papillomavirus-positive (HPV+) oropharyngeal cancer (OPC) has increased rapidly in North America, improved screening and early detection has been a significant focus of research.

Results on Dose Expansion for R3 Combined with RT for Cisplatin-Ineligible LA HNSCC Patients

Chemoradiation with concurrent cisplatin is standard treatment for patients with locally advanced head and neck squamous cell cancer (LA HNSCC). However, many patients are not candidates for cisplatin; treatment options for these patients are limited.

Phase II Trial Shows Promise for Combining Vismodegib and RT in Advanced BCC

For many years, radiation therapy (RT) has been the main treatment for unresectable, locally advanced basal cell carcinoma (BCC). Patients whose tumors are not controlled can experience devastating cancer-related problems such as bleeding and malodor from fungating tumors that are locally destructive.

AI Model Incorporating Features of the Tumor Microenvironment Improves Accuracy of Predicting Extranodal Extension in Oropharyngeal Cancer

Annie Chan, MD, and Rahul Paul, PhD, from the Department of Radiation Oncology at Massachusetts General Hospital, together with their otolaryngology colleague Jeremy Richmon, MD, at the Massachusetts Eye and Ear Infirmary reported on utilizing machine learning and deep learning algorithms that incorporate perinodal microenvironment to improve the performance of their AI model in predicting for extranodal extension (ENE) in patients with oropharyngeal cancer.

Keynote I: Overcoming Structural Barriers to Diverse Representation and Clinical Trials

Yesterday, Carmen Guerra, MD, MSCE, presented an engaging keynote: “Overcoming Structural Barriers to Diverse Representation and Clinical Trials.” Kelly Malloy, MD, of University of Michigan, introduced Dr. Guerra, sharing that Dr. Guerra’s perspective is borne of many critical roles, including as the Ruth C. and Raymond G. Perelman Professor of Medicine at the University of Pennsylvania. She is also a practicing internist and the Associate Director of Diversity and Outreach for the Abramson Cancer Center, where she helps to design and implement interventions to increase the participation of underrepresented populations.

SITC's Certificate in Cancer Immunotherapy

The Society for Immunotherapy of Cancer’s (SITC) Certificate in Cancer Immunotherapy program is designed to offer physicians and health care providers the knowledge and skills to deliver effective care to cancer patients being treated with immunotherapy.

Help Continue the Call on Congress to Address Drug Shortages

Generic drug shortages are a crisis for cancer care in the U.S. Currently, 15 cancer-related drugs are in short supply. To help address this emergency, the American Society of Clinical Oncology and the Association for Clinical Oncology (collectively ASCO) are working to help mitigate the current crisis and prevent similar situations in the future.




Connect With Us: